… RNA base-editing platform technologies – Axiomer ® and Trident ® ProQR has been further optimizing the Axiomer ® … this in H2 2022. ProQR achieved proof of concept for the Trident ® technology in several models showing translational … of nonsense mediated decay. Further optimizations of the Trident ® platform for development purposes are ongoing. …
… pipeline candidates, and to advance our Axiomer ® and Trident ™ RNA-editing technology platforms.” Business … the RNA – an Inosine is translated as a Guanosine (G). Our TRIDENT™ RNA pseudouridylation platform enables the …
… intravitreal injections in the eye. About Axiomer and Trident ProQR is pioneering a next-generation RNA technology … the RNA – an Inosine is translated as a Guanosine (G). Our TRIDENT™ RNA pseudouridylation platform enables the …
Additional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022
Phase 2/3 Sirius and Celeste clinical trials of ultevur
… is on track for late 2024/early 2025. Potential initial Trident preclinical data in late 2024 – Trident is ProQR’s early stage RNA editing pseudouridylation …
… to the clinic in late 2024/early 2025. Potential initial Trident preclinical data in late 2024 – Trident is ProQR’s early stage RNA editing pseudouridylation …
